Why are the Therapeutic Drug Monitoring Results of Voriconazole Inconsistent with CYP2C19 Genetic Testing?

J Coll Physicians Surg Pak. 2023 May;33(5):598-599. doi: 10.29271/jcpsp.2023.05.598.

Authors

Lingti Kong^{1

2

3}, Mengyuan Xie^{1

2

3}, Manxue Jiang^{1

2

3}, Yulin Zhu^{1

2

3}

Affiliations

¹ Department of Pharmacy, the First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
² School of Pharmacy, Bengbu Medical College, Bengbu, China.
³ Institute of Emergency and Critical Care Medicine, the First Affiliated Hospital of Bengbu Medical College, Bengbu, China.

PMID: 37190702
DOI: 10.29271/jcpsp.2023.05.598

Abstract

Null.

MeSH terms

Antifungal Agents* / therapeutic use
Cytochrome P-450 CYP2C19 / genetics
Drug Monitoring*
Genetic Testing
Genotype
Humans
Voriconazole / therapeutic use

Substances

Voriconazole
Antifungal Agents
Cytochrome P-450 CYP2C19
CYP2C19 protein, human